Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21 Read more about Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA Read more about Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference Read more about Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis Read more about FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study Read more about Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study
Amgen Reports First Quarter 2021 Financial Results Read more about Amgen Reports First Quarter 2021 Financial Results
OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis Read more about OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
Amgen Announces Webcast Of 2021 First Quarter Financial Results Read more about Amgen Announces Webcast Of 2021 First Quarter Financial Results
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation Read more about Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
